Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX versus MEASURIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX versus MEASURIN.
ANAPROX vs MEASURIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Measurin is an aspirin preparation that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin and thromboxane synthesis. This results in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
250-500 mg orally twice daily; maximum 1.5 g/day; for extended-release: 375-750 mg orally twice daily
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life 12-17 hours; prolonged in elderly (up to 20 hours) and in renal impairment.
Plasma elimination half-life is 2-3 hours at low doses (antiplatelet) and increases to 15-30 hours at anti-inflammatory doses due to saturation of hepatic metabolism; clinical context: higher doses require longer dosing intervals to avoid accumulation.
Renal excretion of metabolites (95%) and unchanged drug (<5%); biliary/fecal elimination minor (<5%).
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid) accounts for >90% of elimination; minor biliary/fecal excretion (<5%) occurs.
Category C
Category C
NSAID
NSAID